The binding of the HIV envelope glycoprotein, gpl20, to its cell surface receptor, CD4, exposes novel """"""""complex-dependent"""""""" gpl20 epitopes that elicit neutralizing antibody responses. These epitopes are situated in a gpl20 domain that binds 7 transmembrane spanning co-receptors needed for virus entry. Evidence that complex-dependent epitopes might be important vaccine targets was provided by our early studies showing: 1) that covalently crosslinked gp120-CD4 complexes elicit broadly neutralizing humoral responses against primary HIV isolates. In accordance, """"""""fusion competent"""""""" immunogens containing gpl20 that is conformationally altered by cell surface receptor binding were recently shown to elicit broadly neutralizing humoral responses against a wide variety of HIV isolates from different genetic clades. These results warrant the development of vaccine strategies to raise humoral and cellular responses against complex dependent epitopes. Our hypothesis is that this can be accomplished by constructing single chain chimeric molecules comprised of gpl20 and CD4 covalently attached by a polypeptide linker. In this application, we provide preliminary evidence showing that such complexes are expressed from nucleotide sequences encoding codon-optimized gpl20 and soluble CD4. In order to evaluate our hypothesis, we propose to further develop and characterize these molecules, and evaluate their immunogenic properties in the contexts of DNA and subunit vaccines. The work will proceed with two specific aims. The first will include the production and characterization of constructs that express soluble, single-chain CD4-gpl20 complexes from M-tropic (R5), dual-tropic (R5X4) and T-tropic (X4) primary viruses.
The second Aim will be to evaluate the immunogenicity of single chain CD4-gpl20 complexes in human CD4 transgenic mice. This work should provide new data with significant practical and scientific relevance to HIV vaccine development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI047066-01
Application #
6080413
Study Section
Special Emphasis Panel (ZRG1-VACC (03))
Program Officer
Bradac, James A
Project Start
2000-02-15
Project End
2002-01-31
Budget Start
2000-02-15
Budget End
2001-01-31
Support Year
1
Fiscal Year
2000
Total Cost
$222,750
Indirect Cost
Name
University of MD Biotechnology Institute
Department
Type
Organized Research Units
DUNS #
City
Baltimore
State
MD
Country
United States
Zip Code
21202
Fouts, Timothy; Godfrey, Karla; Bobb, Kathryn et al. (2002) Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci U S A 99:11842-7
Devico, Anthony L; Fouts, Timothy R; Shata, Mohamed T et al. (2002) Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine 20:1968-74
Chow, Yen-Hung; Wei, Olivia L; Phogat, Sanjay et al. (2002) Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogens. Biochemistry 41:7176-82
Kamin-Lewis, R; Abdelwahab, S F; Trang, C et al. (2001) Perforin-low memory CD8+ cells are the predominant T cells in normal humans that synthesize the beta -chemokine macrophage inflammatory protein-1beta. Proc Natl Acad Sci U S A 98:9283-8